Eterna Therapeutics INC Form 4 insider transactions

Sandra M. Gurrola, Senior VP of Finance at Ernexa Therapeutics Inc., converted 30 restricted stock units into common stock on June 21, 2025, increasing her direct beneficial ownership of common stock to 110 shares.

Charles Cherington, a Director and 10% owner of Ernexa Therapeutics Inc. (ERNA), has substantially increased his beneficial ownership through a private placement and a stock dividend, now holding over 41 million shares.

Charles Cherington, a director and 10% owner of Ernexa Therapeutics, filed an amended Form 4 to correct the transaction date for the exchange of warrants and convertible notes to September 24, 2024, due to the execution of support agreements that practically assured stockholder approval.

Charles Cherington, a director and 10% owner of Eterna Therapeutics Inc., acquired 3,768,397 shares of common stock through a private placement on April 2, 2025.

Director William Wexler reports acquisition of stock options in Eterna Therapeutics.

Sandra M. Gurrola, Sr. VP of Finance at Eterna Therapeutics Inc., reports the acquisition of stock options.

Director James Arthur Bristol acquired 72,074 stock options in Eterna Therapeutics on February 7, 2025.

Director Peter Cicala acquired stock options for 51,485 shares of Eterna Therapeutics common stock on February 7, 2025.

Eterna Therapeutics CEO Sanjeev Luther reports the acquisition of 1,123,350 stock options in the company.

Director Elena Ratner reports acquisition of stock options in Eterna Therapeutics.

Charles Cherington, a director and 10% owner of Eterna Therapeutics, substantially increased his holdings through the exchange of warrants and convertible notes for common stock, as well as acquiring new convertible notes.

Sandra Gurrola, Sr. VP of Finance at Eterna Therapeutics Inc., reports the vesting and subsequent disposal of shares related to restricted stock units.

Director Peter Cicala reports acquisition of stock options in Eterna Therapeutics Inc.

Sandra M. Gurrola, Sr. VP of Finance at Eterna Therapeutics Inc., acquired 80,000 stock options on April 26, 2024.

Director James Arthur Bristol acquired stock options for 124,525 shares of Eterna Therapeutics Inc. on April 26, 2024.